Surgical & Medical Instruments & Apparatus · SIC 3841

TACTILE SYSTEMS TECHNOLOGY INC

TCMD

Watch

Latest revenue

$75.3M

as of 2026-03-31

Latest net income

$-1.8M

as of 2026-03-31

Net margin

-2.3%

as of 2026-03-31

Price · 5Y

-14.3% / yr 28.1 pts / yr vs S&P 500 53.7% total
Compare:

Live market

delayed ≤15 min
$24.90
2.85%
Market cap
$561.7M
Enterprise value
$561.7M
P/E (trailing)
29.4×
Forward P/E
P/B
Dividend yield
0.0%
52-wk high
$37.77
52-wk low
$9.41
Beta
Shares out
22.6M

5-year trend

What this company does

AI

Overview Tactile Systems Technology, Inc. (“we,” “us,” and “our”) is a medical technology company that develops and provides innovative medical devices for the treatment of underserved chronic diseases. We were originally incorporated in Minnesota under the name Tactile Systems Technology, Inc. on January 30, 1995. During 2006, we established a merger corporation and subsequently, on July 21, 2006, merged with and into this merger corporation resulting in us being reincorporated as a Delaware corporation. The resulting corporation assumed the name Tactile Systems Technology, Inc. and in September 2013, we began doing business as “Tactile Medical”. Our mission is to help people suffering…

AI summary unavailable — showing raw filing excerpt

Generated from TCMD's filing dated 2026-02-17

Key risks

AI

Item 1A. Risk Factors. Risk factors which could cause actual results to differ from our expectations and which could negatively impact our financial condition and results of operations are discussed below and elsewhere in this report. Additional risks and uncertainties not presently known to us or that are currently not believed to be significant to our business may also affect our actual results and could harm our business, financial condition and results of operations. If any of the risks or uncertainties described below or any additional risks and uncertainties actually occur, our business, results of operations and financial condition could be materially and adversely affected. Risks…

AI summary unavailable — showing raw filing excerpt

Generated from TCMD's filing dated 2026-02-17

Profitability

Gross margin

75.9%

2.6%

Operating margin

8.9%

17.4%

Net margin

5.8%

0.1%

Return on equity

8.7%

11.4%

Return on assets

7.0%

22.4%

Leverage

Debt / equity

0.25×

33.0%

Long-term debt / equity

0.11×

20.7%

Debt / assets

20.1%

26.4%

Earnings tracker

QuarterRevenueYoYNet incomeYoYNet margin

Q1 2026

2026-03-31

$75.3M+22.8%$-1.8M+40.7%-2.3%

Q4 2025

2025-12-31

$103.6M+21.0%$13.6M+14.1%13.1%

Q3 2025

2025-09-30

$85.8M+17.3%$8.2M+59.2%9.6%

Q2 2025

2025-06-30

$78.9M+7.8%$243.0K-88.4%0.3%

Q1 2025

2025-03-31

$61.3M+0.3%$-3.0M-34.6%-4.9%

Q4 2024

2024-12-31

$85.6M$11.9M13.9%

Q3 2024

2024-09-30

$73.1M+5.0%$5.2M-74.6%7.1%

Q2 2024

2024-06-30

$73.2M+7.1%$2.1M+2189.0%2.9%

Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.

Industry trend

Surgical & Medical Instruments & Apparatus · SIC 3841

Your notes

Keep private notes on TCMD — thesis, target price, catalysts to watch.

Visible only to you. Never shared. Never used to train AI.

Sign in to write a note

Insider activity

Insider buying

$0

Insider selling

$1.8M

Net activity

−$1.8M

Distinct insiders

3

Open-market trades over the last 365 days.

Recent transactions

DateInsiderTypeSharesPriceValue
2026-05-11

Elaine M. Birkemeyer

CHIEF FINANCIAL OFFICER

Sale4,631$24.49$113.4K
2026-02-24

Sheri Louise Dodd

Chief Executive Officer

Sale10,993$28.94$318.1K
2026-02-24

Elaine M. Birkemeyer

CHIEF FINANCIAL OFFICER

Sale7,701$28.94$222.9K
2026-02-24

Kristie Burns

Sr. VP Mktg & Clinical Affairs

Sale6,246$28.94$180.8K
2026-02-23

Elaine M. Birkemeyer

CHIEF FINANCIAL OFFICER

Sale5,322$28.28$150.5K
2026-02-23

Elaine M. Birkemeyer

CHIEF FINANCIAL OFFICER

Sale196$28.69$5.6K
2026-02-23

Sheri Louise Dodd

Chief Executive Officer

Sale14,703$28.28$415.8K
2026-02-23

Sheri Louise Dodd

Chief Executive Officer

Sale537$28.69$15.4K
2026-02-23

Kristie Burns

Sr. VP Mktg & Clinical Affairs

Sale4,279$28.28$121.0K
2026-02-23

Kristie Burns

Sr. VP Mktg & Clinical Affairs

Sale160$28.69$4.6K
2026-01-02

Kristie Burns

Sr. VP Mktg & Clinical Affairs

Sale5,139$28.85$148.3K
2025-08-08

Sheri Louise Dodd

Chief Executive Officer

Sale7,762$12.36$95.9K

Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.

Who owns TCMD

Institutional value

$236.0M

Total shares held

10.4M

Distinct holders

107

-60 vs prior

As of

2026-03-31

Prior: 2025-12-31

Filers with $100M+ AUM disclose holdings 45 days after quarter end.

Top institutional holders

#ManagerSharesValueQoQ changeAction
1BlackRock, Inc.1.8M$46.5M+8.6K (+0.5%)Added
2DIMENSIONAL FUND ADVISORS LP1.1M$28.2M-15.5K (-1.4%)Trimmed
3VANGUARD CAPITAL MANAGEMENT LLC945.1K$24.7MNew
4VANGUARD PORTFOLIO MANAGEMENT LLC668.3K$17.5MNew
5FEDERATED HERMES, INC.661.0K$17.3M+15.5K (+2.4%)Added
6DEUTSCHE BANK AG\580.8K$15.2M+2.1K (+0.4%)Added
7PINNACLE ASSOCIATES LTD326.8K$8.5M-862 (-0.3%)Trimmed
8UBS Group AG223.6K$5.8M+25.8K (+13.1%)Added
9GLOBEFLEX CAPITAL L P222.3K$5.8M-18.9K (-7.9%)Trimmed
10PRUDENTIAL FINANCIAL INC222.1K$5.8M+171.4K (+337.9%)Added
11Bank of New York Mellon Corp150.9K$3.9M-13.5K (-8.2%)Trimmed
12VANGUARD FIDUCIARY TRUST CO146.8K$3.8MNew
13FRANKLIN RESOURCES INC136.9K$3.6M+90.8K (+197.1%)Added
14O'SHAUGHNESSY ASSET MANAGEMENT, LLC132.0K$3.4M+53.0K (+67.0%)Added
15Invesco Ltd.121.3K$3.2M-39.0K (-24.4%)Trimmed
16Accredited Investors Inc.94.9K$2.5M-20.5K (-17.7%)Trimmed
17Kopp Family Office, LLC85.0K$2.2M-42.3K (-33.2%)Trimmed
18BURNEY CO/78.9K$2.1MNew
19SummerHaven Investment Management, LLC78.6K$2.1M-3.9K (-4.8%)Trimmed
20Integrated Quantitative Investments LLC76.0K$2.0M+42.4K (+126.0%)Added

Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.

Top questions investors are asking

Coming once TCMD's latest filing finishes processing.